Protease-Activating CD45-Gate CAR for Cancer Treatment

ChangeBridge: EPO Bulletin - Biotech (C12N)

Published March 25th, 2026

Detected April 2nd, 2026

Summary

The European Patent Office published patent application EP4263590A1 for Allogene Therapeutics and Pfizer's protease-activating CD45-gate chimeric antigen receptor (CAR) technology for cancer treatment. The patent covers engineered T-cells with protease-activated gating mechanisms and applications in oncology.

View original document View source feed page

What changed

EPO published patent application EP4263590A1 titled 'Protease-Activating CD45-Gate CAR' filed by Allogene Therapeutics and Pfizer. The invention relates to engineered immune cells with conditional activation mechanisms using CD45-gate technology for targeted cancer treatment. IPC classifications include C07K 14/705, C07K 14/725, C12N 9/16, and A61P 35/00.

This is a patent publication notice rather than a regulatory action. No compliance obligations arise from this document. Competitors developing similar CAR-T technologies should review this patent to assess potential freedom-to-operate implications. The designated states cover all major European Economic Area countries.

Source document (simplified)

← EPO Patent Bulletin

PROTEASE-ACTIVATING CD45-GATE CAR

Publication EP4263590A1 Kind: A1 Mar 25, 2026

Applicants

Allogene Therapeutics, Inc., Pfizer Inc.

Inventors

LANG, Shanshan, VAN BLARCOM, Thomas John, BETHUNE, Michael Thomas, PANOWSKI, Siler, TAN, Nguyen, ZHANG, Yi, SASU, Barbra Johnson, LI, Zhe

IPC Classifications

C07K 14/705 20060101AFI20220701BHEP C07K 14/725 20060101ALI20220701BHEP C07K 14/715 20060101ALI20220701BHEP C12N 9/16 20060101ALI20220701BHEP A61K 38/17 20060101ALI20220701BHEP A61K 35/17 20150101ALI20220701BHEP A61P 35/00 20060101ALI20220701BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →